



Press release
June 22, 2016
Gothenburg

Lung Cancer Patient given Chemotherapy through In Vivo Lung Perfusion with STEEN Solution™

STEEN Solution™ was used for the first time to give localized delivery of a chemotherapy agent to a patient suffering from metastatic lung sarcoma through In-Vivo Lung Perfusion (IVLP). This was also the first time STEEN Solution was used to perfuse a lung on In-Vivo i.e. on a living patient. The aim of the study is to prove safety and evaluate the ability to use STEEN Solution™ to improve isolated tissue therapy.

A leading hospital enrolled their first patient into a clinical trial to provide chemotherapy to patients suffering from lung sarcomas. According to the 2016 data from the American Cancer Society, soft tissue sarcomas affect approximately 12,310 people annually in the United States and more than 4,990 Americans will die each year of this disease. Of the patients who develop extremity sarcoma, approximately 20% will have isolated pulmonary metastatic disease at some point in the course of their disease. Surgery is the preferred way of treating pulmonary sarcomas but due to micrometastasis, that cannot be seen, the person has a greater than 70% risk of pulmonary recurrence after this surgery. The use of systemic chemotherapy has not been used due to the significant side effects with unproven benefit. With the use of in-vivo lung perfusion the surgeon can shut off the lung from the systemic circulation and give the chemotherapy only to the lung so as not to affect the rest of the body.

“This is a significant step forward in expanding the capability of IVLP in cancer therapy. The dosage of chemotherapy given is yet to be determined to give optimal therapy with reduced side effects but this is the beginning of a new chapter in cancer therapy”, says Magnus Nilsson, CEO of XVIVO Perfusion.

June 22, 2016
Gothenburg
XVIVO Perfusion AB (publ)

For further information please contact:

Christoffer Rosenblad, CFO, tel: +1 720 616 2101, email: christoffer.rosenblad@xvivoperfusion.com

Magnus Nilsson, CEO, tel +46 31 788 2150, email: magnus.nilsson@xvivoperfusion.com

XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation. The company is headquartered in Gothenburg, Sweden, and has one office in the USA. The XVIVO share is listed on Nasdaq First North Premier and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.

Tel: +46 31 788 21 50. Fax: +46 31 788 21 69.

E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com

The information was submitted for publication on June 22, 2016 at 8:30 a.m.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.